Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Atrial fibrillation is a marker of increased mortality risk in non-ischemic heart failure - results from the DANISH Trial

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Boas, Rune ; Thune, Jens Jakob ; Pehrson, Steen ; Køber, Lars ; Nielsen, Jens C ; Videbæk, Lars ; Haarbo, Jens ; Korup, Eva ; Bruun, Niels Eske ; Brandes, Axel ; Eiskjær, Hans ; Thøgersen, Anna M ; Philbert, Berit T ; Svendsen, Jesper Hastrup ; Dixen, Ulrik. / Atrial fibrillation is a marker of increased mortality risk in non-ischemic heart failure - results from the DANISH Trial. In: American Heart Journal. 2021 ; Vol. 232. pp. 61-70.

Bibtex

@article{dee50ed4aa0a40a5aa755c6ecc0d9e2d,
title = "Atrial fibrillation is a marker of increased mortality risk in non-ischemic heart failure - results from the DANISH Trial",
abstract = "Background: Atrial fibrillation (AF) in heart failure (HF) patients has been associated with a worse outcome. Similarly, excessive supraventricular ectopic activity (ESVEA) has been linked to development of AF, stroke, and death. This study aimed to investigate AF and ESVEA's association with outcomes and effect of prophylactic implantable cardioverter defibrillator (ICD) implantation in nonischemic HF patients. Methods: A total of 850 patients with nonischemic HF, left ventricle ejection fraction ≤35%, and elevated N-terminal pro-brain natriuretic peptides underwent 24 hours Holter recording. The presence of AF (≥30 seconds) and ESVEA (≥30 supraventricular ectopic complexes (SVEC) per hour or run of SVEC ≥20 beats) were registered. Outcomes were all-cause mortality, cardiovascular death (CVD), and sudden cardiac death (SCD). Results: AF was identified in 188 patients (22%) and ESVEA in 84 patients (10%). After 4 years and 11 months of follow-up, a total of 193 patients (23%) had died. AF was associated with all-cause mortality (hazard ratio [HR] 1.44; confidence interval [CI] 1.04-1.99; P = .03) and CVD (HR 1.59; CI 1.07-2.36; P = .02). ESVEA was associated with all-cause mortality (HR 1.73; CI 1.16-2.57; P = .0073) and CVD (HR 1.76; CI 1.06-2.92; P = .03). Neither AF nor ESVEA was associated with SCD. ICD implantation was not associated with an improved prognosis for neither AF (P value for interaction = .17), nor ESVEA (P value for interaction = .68). Conclusions: Both AF and ESVEA were associated with worsened prognosis in nonischemic HF. However, ICD implantation was not associated with an improved prognosis for either group.",
author = "Rune Boas and Thune, {Jens Jakob} and Steen Pehrson and Lars K{\o}ber and Nielsen, {Jens C} and Lars Videb{\ae}k and Jens Haarbo and Eva Korup and Bruun, {Niels Eske} and Axel Brandes and Hans Eiskj{\ae}r and Th{\o}gersen, {Anna M} and Philbert, {Berit T} and Svendsen, {Jesper Hastrup} and Ulrik Dixen",
note = "Copyright {\textcopyright} 2020 Elsevier Inc. All rights reserved.",
year = "2021",
month = feb,
day = "1",
doi = "10.1016/j.ahj.2020.10.073",
language = "English",
volume = "232",
pages = "61--70",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby, Inc",

}

RIS

TY - JOUR

T1 - Atrial fibrillation is a marker of increased mortality risk in non-ischemic heart failure - results from the DANISH Trial

AU - Boas, Rune

AU - Thune, Jens Jakob

AU - Pehrson, Steen

AU - Køber, Lars

AU - Nielsen, Jens C

AU - Videbæk, Lars

AU - Haarbo, Jens

AU - Korup, Eva

AU - Bruun, Niels Eske

AU - Brandes, Axel

AU - Eiskjær, Hans

AU - Thøgersen, Anna M

AU - Philbert, Berit T

AU - Svendsen, Jesper Hastrup

AU - Dixen, Ulrik

N1 - Copyright © 2020 Elsevier Inc. All rights reserved.

PY - 2021/2/1

Y1 - 2021/2/1

N2 - Background: Atrial fibrillation (AF) in heart failure (HF) patients has been associated with a worse outcome. Similarly, excessive supraventricular ectopic activity (ESVEA) has been linked to development of AF, stroke, and death. This study aimed to investigate AF and ESVEA's association with outcomes and effect of prophylactic implantable cardioverter defibrillator (ICD) implantation in nonischemic HF patients. Methods: A total of 850 patients with nonischemic HF, left ventricle ejection fraction ≤35%, and elevated N-terminal pro-brain natriuretic peptides underwent 24 hours Holter recording. The presence of AF (≥30 seconds) and ESVEA (≥30 supraventricular ectopic complexes (SVEC) per hour or run of SVEC ≥20 beats) were registered. Outcomes were all-cause mortality, cardiovascular death (CVD), and sudden cardiac death (SCD). Results: AF was identified in 188 patients (22%) and ESVEA in 84 patients (10%). After 4 years and 11 months of follow-up, a total of 193 patients (23%) had died. AF was associated with all-cause mortality (hazard ratio [HR] 1.44; confidence interval [CI] 1.04-1.99; P = .03) and CVD (HR 1.59; CI 1.07-2.36; P = .02). ESVEA was associated with all-cause mortality (HR 1.73; CI 1.16-2.57; P = .0073) and CVD (HR 1.76; CI 1.06-2.92; P = .03). Neither AF nor ESVEA was associated with SCD. ICD implantation was not associated with an improved prognosis for neither AF (P value for interaction = .17), nor ESVEA (P value for interaction = .68). Conclusions: Both AF and ESVEA were associated with worsened prognosis in nonischemic HF. However, ICD implantation was not associated with an improved prognosis for either group.

AB - Background: Atrial fibrillation (AF) in heart failure (HF) patients has been associated with a worse outcome. Similarly, excessive supraventricular ectopic activity (ESVEA) has been linked to development of AF, stroke, and death. This study aimed to investigate AF and ESVEA's association with outcomes and effect of prophylactic implantable cardioverter defibrillator (ICD) implantation in nonischemic HF patients. Methods: A total of 850 patients with nonischemic HF, left ventricle ejection fraction ≤35%, and elevated N-terminal pro-brain natriuretic peptides underwent 24 hours Holter recording. The presence of AF (≥30 seconds) and ESVEA (≥30 supraventricular ectopic complexes (SVEC) per hour or run of SVEC ≥20 beats) were registered. Outcomes were all-cause mortality, cardiovascular death (CVD), and sudden cardiac death (SCD). Results: AF was identified in 188 patients (22%) and ESVEA in 84 patients (10%). After 4 years and 11 months of follow-up, a total of 193 patients (23%) had died. AF was associated with all-cause mortality (hazard ratio [HR] 1.44; confidence interval [CI] 1.04-1.99; P = .03) and CVD (HR 1.59; CI 1.07-2.36; P = .02). ESVEA was associated with all-cause mortality (HR 1.73; CI 1.16-2.57; P = .0073) and CVD (HR 1.76; CI 1.06-2.92; P = .03). Neither AF nor ESVEA was associated with SCD. ICD implantation was not associated with an improved prognosis for neither AF (P value for interaction = .17), nor ESVEA (P value for interaction = .68). Conclusions: Both AF and ESVEA were associated with worsened prognosis in nonischemic HF. However, ICD implantation was not associated with an improved prognosis for either group.

UR - http://www.scopus.com/inward/record.url?scp=85097392998&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2020.10.073

DO - 10.1016/j.ahj.2020.10.073

M3 - Journal article

C2 - 33144085

VL - 232

SP - 61

EP - 70

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -

ID: 61235275